Welcome to our 2024 Impact Report – a look at what our portfolio companies have done to move the needle. This year’s edition highlights the grit, progress and potential of impact startups in a world that feels anything but predictable. It’s a snapshot of where we are, what we’ve learned, and why we believe the case for impact has never been stronger.
Our healthcare systems were built to treat acute illness. Chronic disease doesn’t fit that model. Millions of patients face long waiting times, limited access to specialised clinicians, and care pathways that still rely heavily on in-person visits. At the same time, demand is rising and healthcare workforces are shrinking.
The gap keeps widening.
That’s why we’ve invested in Oviva.
The Problem
Across Europe, more than 200 million adults live with obesity and related chronic conditions. Yet access to effective, long-term care remains limited.
Health systems are under pressure from every direction: rising chronic disease prevalence, shortages of specialised clinicians, long waits for structured care programmes, and delivery models that simply don’t scale. For many patients, the result is delayed intervention. Or no intervention at all.
The Solution
Oviva was built to close this gap. Its certified digital therapy programmes are fully reimbursed by statutory health insurers and national health systems in Germany, Switzerland, and the UK. Through accredited digital healthcare applications, patients get access to structured, multidisciplinary care — without long delays, and independent of location.
Kai Eberhardt, CEO and Co-Founder of Oviva: “This investment allows us to do what we set out to do: make effective care accessible to everyone who needs it. By intervening earlier and supporting patients continuously over time, we help prevent disease progression, free up clinical capacity, and enable healthcare systems to deliver better outcomes with limited resources.”
To date, Oviva has supported more than one million people in improving their health through evidence-based lifestyle and behavioural interventions — a European milestone for digital healthcare. The clinical impact is well documented, with more than 90 peer-reviewed abstracts and publications demonstrating sustained outcomes across large patient populations.
Oviva’s platform combines a medical-device-certified app with access to multidisciplinary care teams. AI is embedded across the platform to personalise treatment pathways, support clinicians in their day-to-day work, and ensure high-quality delivery at scale — improving the patient experience while helping address workforce shortages, without compromising clinical standards.
The Round
Oviva has raised €200 million in Series D financing, comprising a mix of primary and secondary capital. The round is led by Kinnevik, with participation from A.P. Moller Holding, Planet First Partners, Lunate, EGS Beteiligungen AG, and Norrsken VC, alongside continued support from existing investor Sofina.
The capital will support rising demand for reimbursed digital healthcare and enable expansion into additional chronic indications, including hypertension and type 2 diabetes — helping prevent and manage costly comorbidities. Oviva will also continue to advance its AI-powered tools to better support both patients and clinicians.
Founded in 2014, Oviva has steadily expanded across European markets and reached cash-flow profitability in 2025 — a strong signal of the sustainability of its reimbursed care model.
Proud to back the team as they build the tools for a healthier future.
Curious to learn more? Visit oviva.com.
